169 related articles for article (PubMed ID: 34569417)
21. Reduced maximal inhibition in phenotypic susceptibility assays indicates that viral strains resistant to the CCR5 antagonist maraviroc utilize inhibitor-bound receptor for entry.
Westby M; Smith-Burchnell C; Mori J; Lewis M; Mosley M; Stockdale M; Dorr P; Ciaramella G; Perros M
J Virol; 2007 Mar; 81(5):2359-71. PubMed ID: 17182681
[TBL] [Abstract][Full Text] [Related]
22. C-C chemokine receptor type 5 (CCR5) utilization of transmitted and early founder human immunodeficiency virus type 1 envelopes and sensitivity to small-molecule CCR5 inhibitors.
Hu Q; Huang X; Shattock RJ
J Gen Virol; 2010 Dec; 91(Pt 12):2965-73. PubMed ID: 20810746
[TBL] [Abstract][Full Text] [Related]
23. HIV-1 escape from the CCR5 antagonist maraviroc associated with an altered and less-efficient mechanism of gp120-CCR5 engagement that attenuates macrophage tropism.
Roche M; Jakobsen MR; Sterjovski J; Ellett A; Posta F; Lee B; Jubb B; Westby M; Lewin SR; Ramsland PA; Churchill MJ; Gorry PR
J Virol; 2011 May; 85(9):4330-42. PubMed ID: 21345957
[TBL] [Abstract][Full Text] [Related]
24. Pharmacophore-Oriented Identification of Potential Leads as CCR5 Inhibitors to Block HIV Cellular Entry.
Singh P; Kumar V; Lee G; Jung TS; Ha MW; Hong JC; Lee KW
Int J Mol Sci; 2022 Dec; 23(24):. PubMed ID: 36555761
[TBL] [Abstract][Full Text] [Related]
25. A single-residue change in the HIV-1 V3 loop associated with maraviroc resistance impairs CCR5 binding affinity while increasing replicative capacity.
Garcia-Perez J; Staropoli I; Azoulay S; Heinrich JT; Cascajero A; Colin P; Lortat-Jacob H; Arenzana-Seisdedos F; Alcami J; Kellenberger E; Lagane B
Retrovirology; 2015 Jun; 12():50. PubMed ID: 26081316
[TBL] [Abstract][Full Text] [Related]
26. New insights into the mechanisms whereby low molecular weight CCR5 ligands inhibit HIV-1 infection.
Garcia-Perez J; Rueda P; Staropoli I; Kellenberger E; Alcami J; Arenzana-Seisdedos F; Lagane B
J Biol Chem; 2011 Feb; 286(7):4978-90. PubMed ID: 21118814
[TBL] [Abstract][Full Text] [Related]
27. Molecular interactions of CCR5 with major classes of small-molecule anti-HIV CCR5 antagonists.
Kondru R; Zhang J; Ji C; Mirzadegan T; Rotstein D; Sankuratri S; Dioszegi M
Mol Pharmacol; 2008 Mar; 73(3):789-800. PubMed ID: 18096812
[TBL] [Abstract][Full Text] [Related]
28. Estimating the threshold surface density of Gp120-CCR5 complexes necessary for HIV-1 envelope-mediated cell-cell fusion.
Mulampaka SN; Dixit NM
PLoS One; 2011; 6(5):e19941. PubMed ID: 21647388
[TBL] [Abstract][Full Text] [Related]
29. A study of the molecular mechanism of binding kinetics and long residence times of human CCR5 receptor small molecule allosteric ligands.
Swinney DC; Beavis P; Chuang KT; Zheng Y; Lee I; Gee P; Deval J; Rotstein DM; Dioszegi M; Ravendran P; Zhang J; Sankuratri S; Kondru R; Vauquelin G
Br J Pharmacol; 2014 Jul; 171(14):3364-75. PubMed ID: 24628038
[TBL] [Abstract][Full Text] [Related]
30. Allosteric model of maraviroc binding to CC chemokine receptor 5 (CCR5).
Garcia-Perez J; Rueda P; Alcami J; Rognan D; Arenzana-Seisdedos F; Lagane B; Kellenberger E
J Biol Chem; 2011 Sep; 286(38):33409-21. PubMed ID: 21775441
[TBL] [Abstract][Full Text] [Related]
31. Maraviroc: a new CCR5 antagonist.
Sayana S; Khanlou H
Expert Rev Anti Infect Ther; 2009 Feb; 7(1):9-19. PubMed ID: 19622053
[TBL] [Abstract][Full Text] [Related]
32. Clinical utility of maraviroc.
Parra J; Portilla J; Pulido F; Sánchez-de la Rosa R; Alonso-Villaverde C; Berenguer J; Blanco JL; Domingo P; Dronda F; Galera C; Gutiérrez F; Kindelán JM; Knobel H; Leal M; López-Aldeguer J; Mariño A; Miralles C; Moltó J; Ortega E; Oteo JA
Clin Drug Investig; 2011; 31(8):527-542. PubMed ID: 21595497
[TBL] [Abstract][Full Text] [Related]
33. V3 determinants of HIV-1 escape from the CCR5 inhibitors Maraviroc and Vicriviroc.
Berro R; Klasse PJ; Jakobsen MR; Gorry PR; Moore JP; Sanders RW
Virology; 2012 Jun; 427(2):158-65. PubMed ID: 22424737
[TBL] [Abstract][Full Text] [Related]
34. [Conclusions and perspectives. Maraviroc].
Alcamí J
Enferm Infecc Microbiol Clin; 2008 Oct; 26 Suppl 11():49-54. PubMed ID: 19133222
[TBL] [Abstract][Full Text] [Related]
35. Characterization of HIV-1 entry inhibitors with broad activity against R5 and X4 viral strains.
Sironi F; Malnati M; Mongelli N; Cozzi P; Guzzo C; Ghezzi S; Martínez-Romero C; García-Sastre A; Lusso P; Jabes D; Biswas P
J Transl Med; 2015 Apr; 13():107. PubMed ID: 25888743
[TBL] [Abstract][Full Text] [Related]
36. CCR5 antagonist TD-0680 uses a novel mechanism for enhanced potency against HIV-1 entry, cell-mediated infection, and a resistant variant.
Kang Y; Wu Z; Lau TC; Lu X; Liu L; Cheung AK; Tan Z; Ng J; Liang J; Wang H; Li S; Zheng B; Li B; Chen L; Chen Z
J Biol Chem; 2012 May; 287(20):16499-509. PubMed ID: 22447925
[TBL] [Abstract][Full Text] [Related]
37. Maraviroc (UK-427,857), a potent, orally bioavailable, and selective small-molecule inhibitor of chemokine receptor CCR5 with broad-spectrum anti-human immunodeficiency virus type 1 activity.
Dorr P; Westby M; Dobbs S; Griffin P; Irvine B; Macartney M; Mori J; Rickett G; Smith-Burchnell C; Napier C; Webster R; Armour D; Price D; Stammen B; Wood A; Perros M
Antimicrob Agents Chemother; 2005 Nov; 49(11):4721-32. PubMed ID: 16251317
[TBL] [Abstract][Full Text] [Related]
38. Maraviroc: a review of its use in HIV infection and beyond.
Woollard SM; Kanmogne GD
Drug Des Devel Ther; 2015; 9():5447-68. PubMed ID: 26491256
[TBL] [Abstract][Full Text] [Related]
39. [Mechanisms of resistance and failure of treatment with maraviroc].
Delgado R
Enferm Infecc Microbiol Clin; 2008 Oct; 26 Suppl 11():28-33. PubMed ID: 19133219
[TBL] [Abstract][Full Text] [Related]
40. CCR5 antagonism in HIV infection: current concepts and future opportunities.
Wilkin TJ; Gulick RM
Annu Rev Med; 2012; 63():81-93. PubMed ID: 22034870
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
